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The Context ofGenetic Screening
PAUL R. BILLINGS, M.D., Ph.D.
Clinical genetics is practiced and experienced in a contextual environment. The
context affects the conduct ofprofessional activities and alters that most important
and keyrelationship practitioners developwith their clients. It ismy contention that,
like gene action, clinical genetic practice cannot be understood separately from the
environment inwhich it is delivered. In fact, the revolutionwhich is altering medical
genetics, and rapidly expanding its relevance to the general public, may also
necessitate areaffirmation ofimportant rights andprinciplesgranted inthesocietyin
which geneticists work. A restatement that individuals have freedom of choice in
personal health matters, the right towork and to conduct this pursuit in a safe place,
the right to privacy, and the right to certain entitlements, including adequate health
care and the ability to insure the economic safety ofthe family, needs to accompany
the "genetic revolution."
It is imperative that clinical geneticists champion the necessary entitlements of
their clients, in order to be more effective professionals and to ensure that human
genetics will not become an overly expensive, excessively test-based, elite discipline.
There are some members of our society who view the provision of adequate health
care not as a natural entitlement or right, but rather as a product to be bartered and
purchased for significant profits, ifpossible. There is, however, agrowingcommunity
consensus demanding universally available quality health care, greater personal
freedom, and the ability to pass on a secure financial legacy to heirs. There is, at the
same time, a growing revulsion at the cost and style of our current health and
personal insurance systems. The "new genetics" should affirm a broad range of
individual rights.
Two publications exist which describe key aspects of the environment in which
clinical genetics is currently practiced in this country. One is an article, by Debra S.
Stone in Social Research, which outlines social forces shaping the arena in which
clinical genetics is now conducted [1]. The other document is a report of the
American Council of Life Insurance, authored by Dr. Robert Pokorski [2]. This
pamphlet, along with the National Association of Insurance Commissioners Model
Regulations, clarifies the positions taken by the life and health insurance industries
towardgenetictesting and itsrole inthe insurancebusiness. It isextremelyimportant
that the public become aware of this stance, as the insurance industry wields
tremendous political, economic, and social power.
There are several facts which are not covered in the insurance industry-generated
document. There are approximately 30 to 50 million people in this country who do
not have adequate health insurance. Indivduals without such health entitlements
endure significant suffering in this society, most directly by receiving poor medical
care. Insurance in this country (life and/or health) is produced by a collaboration
among the private insurance industry, employers, and the government; the state and
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federal governments help insurers by giving tax considerations to employers for
providing group health insurance, through direct payments like Medicaid and
Medicare, and, in some venues, through financing state-wide high-risk insurance
pools.
Increasingly, employers "self-insure," which means that they themselves provide
group health and life insurance, sometimes with the advice or management of
representatives of the private insurance industry. This process unites, for practical
purposes, the hiring decision with that ofinsuring.
Insurers, to the extent that they are restrained by law, are regulated at the state
level, where they also have significant political influence through lobbyists. Employ-
ers' behaviors in pre-employment and otherwork settings are virtually uncontrolled,
except when gross discriminatory activity can be proved, in some federally funded
settings, and in states where strict rules control employers' actions. The effect ofthe
recently enacted Americans with Disabilities Act remains uncertain. The effective-
ness of regulations designed to retard insurer and employer discrimination is
uncertain, especially when economic conditions encourage, and individuals or orga-
nizations intend, violations ofrules [3].
It is notable that investors in insurance companies, even during the "genetic
revolution" and in the age of human immunodeficiency virus (HIV), still make
significant profits and the executives of large insurance companies maintain life
styles consistent with the upper classes in our society. Furthermore, this profitable
business has been developed with genetic conditions present in the population it
serves. The incidence of inherited conditions has not been increasing and will not
likely increase in the foreseeable future. Why new detection methods such as
DNA-based testsshouldadverselyaffect anindustryinwhichpremiums are based on
known and stable disease occurrence rates is not clear.
In the past, our ignorance about how genes act has often been exceeded by the
ignorance of those using genetic information for social, economic, and political
purposes [4]. Clinical geneticists sometimes seem content to dismiss past collabora-
tions with the eugenicists as far-off ancient history. Yet in environments where
racism is institutionalized and culturally acceptable, there is, even today, a tendency
to use the "new genetics" to promote a particular world view under the guise of
investigating and applying "scientific fact." For instance, in South Africa, Japan,
Singapore, Malaysia, and othercountries, genetic information seems tobe utilized to
justify prejudices and social stratification not inherent in human societies [5].
Though there have been historical problems in applyinggeneticfindings to benefit
humans, there have also been shining successes. In those disorders which have a
simple genetic mechanism, many families have been helped by classical and newer
approaches. Biochemical assays and prenatal screening have provided significant
benefits, though there have also been costs. For example, genetic counseling is not
always successful. Clients often remain confused aftermultiplecounselingsessions, a
phenomenon which has been documented in several studies [6]. This finding may
have to dowith the type ofservice offered, orthere may have been selection biases in
these studies. Still, miscommunication may result from the nature ofthe information
which clinical geneticists try to impart. There may be important resistances to
hearing and understanding hereditary information [7].
Certainly, my clinical experiences have suggested several "truths" about human
genetics.
48THE CONTEXT OF GENETIC SCREENING
Truth 1. Clinicalgenetics ispracticed bypeople, biasedindividuals whomakemistakes.
Furthermore, thehereditaryinformation thatisofferedingeneticcounselingoftensuggests
that the cause ofan illness is known when evidence conceming how genes produce a
humanpathophysiologicalprocess isactuallynotavailable.
Is there evidence that clinical geneticists are fallible? For almost any counseling
question (it does not matter what the question is!), a broad range ofopinion among
counselors from different countries exists on how to deal with a particular genetic
issue [8]. This variation indicates that the same basic genetic data differ in impor-
tance by context and that an individual counselor's world view and fallibility play a
role in delivery ofservice.
How do we know that genetic causation is misunderstood? Consider the field of
behavioral genetics. It has become generally accepted that specific genes determine
behavior and psychiatric illnesses, yet the data supporting this hypothesis are
generally poor. In fact, the predominance of evidence supports the idea that no
simple genetic mechanism controls any behavior or mental condition [9]. Further-
more, in well-studied genetic conditions such as sickle-cell anemia and phenylketo-
nuria (PKU), how hemoglobin S produces illness or phenylalanine causes retarded
mental development still remain unclear-despite precise genetic information about
these disorders having been available for many years.
Truth 2. Clinical geneticists are affected by the economic environment theypractice in
andarepoorlycompensated.
My salary is important to me. Clinical geneticists, like other professionals in
"cognitive practice," are relatively poorly compensated. Medical geneticists are, in
fact, usually financially dependent on lab assays and chargeable procedures, research
grants with exorbitant overheads, and, to some extent, state budgets. Clinical
geneticists often have to endure ambivalent relations with hospital officials because
their specialty does not perform economically, as does cardiology. Medical genetics is
not currently listed on the rosterofapproved specialties maintained by the American
Medical Association, which may suggest professional, political, economic, and
historical forces inhibiting the growth ofclinical genetic practice.
Hospitals are suffering economically as well because they are not being paid for
uninsured patients, and compensation for the underinsured, who may require
high-cost services, is falling. Many hospitals have responded to this situation by
investing in billing procedures which highlight more serious, chronic, disabling
disorders for the purpose of deriving better payment from third parties who use
diagnostic-related-group (DRG) systems. This process therefore tends to increase
the number of individuals who, at one time, have been labeled with economically
significant DRG illnesses. Some of these individuals may undeservedly suffer social
consequences long after these diagnoses are concocted.
Manifestations of the economic pressures on clinical geneticists are apparent.
Clients are defined as "high-risk," which is a statistical, economic, and culturally
defined notion, having little to do with their individual personal experience or
valuation of a particular condition. For example, women older than 35 years of age,
who are pregnant, are often called "high-risk." Likewise, children who are homozy-
gous for the disease alleles at the alpha-1-antitryspin locus are similarly categorized.
Yet in both these labeled groups, most individuals will not suffer significant disabili-
ties. More than 90 percent of pregnant women above the age of 35 do not give birth
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to a disabled child, and more than 90percent ofthe childrenwho are homozygous for
the alpha-1-antitrypsin disease alleleswill not have childhood liverdisease. Similarly,
non-obedient or "non-compliant" patients can suffer because of appellations that
professionals apply.
This use oflanguage to describe clients is important. Earlier in this conference, it
was stated that a genetic test "might save a muscle biopsy by diagnosing an illness at
the level of the gene." Yet illnesses do not exist in DNA sequences; illness is a
disruption in the functioning ofan individual and the experience ofthis change. This
type ofmisuse oflanguage pervades ourprofession and influences it. Why is it done?
In part, it is to garnerpayment from thirdparites and tojustifythe consultationsfrom
prepaid physician and health maintenance organizations.
In addition, the current environment encourages health professionals, including
medical geneticists, to provide third partieswith confidential health information, for
billing purposes, which is then codified in insurance company data banks. These
computer records of personal information are often maintained without the knowl-
edge of the individuals who are described. The records can be inaccurate. These
practices have in the past been critically scrutinized by the federal agencies.
Regulators took issue with the handling of this private information and the type of
data thatwere stored. Thoughmodified, the problematicpracticescontinue. Further-
more, photocopies of patients' charts are sent to lawyers, insurers, employers, and
other third parties. Put simply, the system as it currently functions alters the way
clients are described and frequentlyviolates their right to privacy.
Truth 3. Parties other than genetic professionals and affectedfamilies are promoting
genetic screening.
Certainly, companies producing genetic products have shown interest in promot-
ing and selling new tests. Shortly after the American Society of Human Genetics
issued a statement discouraging widespread cystic fibrosis (CF) testing, companies
offering DNA tests in Massachusetts began arranging CF testing without genetic
counselingfor anypersonwhorequested it. Howeffective genetic screeningwill be in
environments influenced by economically weak, unregulated, biotechnology compa-
nies remains to be seen.
The insurance industry believes that it has the right to evaluate personal genetic
information now and in the future. Insurers currently try to "cream off" high-risk
individuals within covered populations through a variety of underwriting practices,
an insurance business euphemism for personal investigations. Though insurance
industry representatives often state that their companies are not likely to conduct
genetic screening now or in the foreseeable future, they demand access to this
personal information if it is available at professionals' offices, employment settings,
orgovermental agencies.
Insurers may use genetic information to make coverages for clients with "high-
risk" test results too expensive or limited. Other companies deny coverage, cancel
existing policies, or make claims bureaucracies and procedures so unresponsive that
insurance benefits are functionally not available. This response can occur as a result
of insignificant genetic information. Genetic test results are and will be another
factor used to limit individuals' access to necessary entitlements if current social
conditions persist.
There is no evidence that individuals identified byHIV testing or newgenetic tests
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are really going to affect the profitability ofinsurance companies. This industry fear,
termed "adverse riskselection," has notbeen shown tobe economically important at
present nor to require a business or regulatory response. Yet insurance companies
persist in using the possibility ofthis phenomenon tojustifyviolatingpersonal rights.
In addition, employers seem interested in identifying poorly productive employ-
ees, those who may need safer and possibly more costly environments, as well as
individuals who may disproportionately consume insurance benefits. Thus, employ-
ers and insurers can have similar economic interests in labeling individuals. Also,
goverments facedwith escalatingcosts for health care maybe interested in categoriz-
ing people at "high risk" by supposedly predictive genetic testing. Social planning
and "tracking" for educational or budgeting purposes might be the justification for
this government effort.
The attitudes of these institutions (employers, insurers, governments, adoption
agencies, and the like) influence clinical geneticists because they are dependent on
them for their livelihoods and regularly collaborate with them. Unfortunately, the
professional opinions of experts have little demonstrable influence on decisions
made by these agencies. For instance, insurers do not often consider doctors'
opinions about the health and insurability of individuals. Physicians' statements
about the clinical insignificance of a diagnosis for an individual rarely reverses
exclusion decisions ifthe condition appears on the proscribed list. Recently, a case in
Massachusetts was publicized when a jury, despite seemingly conclusive DNA
identification evidence exonerating a defendant, convicted this individual, despite
testimony provided by geneticists and the evidence of genetic testing. This result
suggests that the pronouncements of experts can be ineffective in countering
personal and public opinion, and institutional policy.
Many ofthe findings noted in this report are indicated by the close examination of
29 cases generated in a survey ofgenetically based discrimination [10]. This research
was conducted using a mailing, advertisements, and personal communications. Most
individuals had suffered insurance discrimination in multiple forms. Significant
problems in employment settings, with governments, and in negotiating adoptions
were also noted.
Finally, there is evidence that therapies for individuals with hereditary disorders
are restricted in our society. Families afflicted with PKU are sometimes termed
"non-compliant" because they cannot afford the expensive diet. A case in Boston of
an individual who needed transplantation surgery and who was denied coverage
because he could not prove that his disorderwas not a "pre-existingcondition" is the
ultimate hereditary Catch-22. Expensive gene-based therapies will probably be
available only to research subjects, the rich, and the insured in our society.
In conclusion, new DNA-based information is revolutionizing the practice of
medical genetics. There are increasingpublic expectations ofthis discipline. There is
also a changing economicenvironment that imposesunique pressures on the practice
ofclinicalgenetics. New research into our trade is needed so that these pressures can
be dealt with reasonably and good counseling delivered.
Many social factors increase the burden suffered by individuals after a genetic
diagnosis. These include: designation as "handicapped," "non-compliant," or"high-
risk"; limitation ofpost-test entitlements, including the right to work, to health care,
to the financial safety ofone's family and other distinctions; associated violations of
privacy and other civil rights; residence in a society that tolerates racism or other
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forms of unfair discrimination; and residence in a society where misconceptions
about the importance of gene effects are rampant. These factors all exist in our
country today. I believe they could be studied and modified.
Finally, practitioners ofgeneticsmightplayaleading role in lesseningsociety-wide
prejudice against thosewithgenetic conditions. The public couldbe taught thatwhat
is considered a genetic trait or disorder has varied with historical time and environ-
ment and will continue to do so; genetic variation is the norm in populations; genes
do not determine illness nor are the causal mechanisms ofillnesses termed "genetic
diseases" often understood; variable expression of genes is common, making the
positive predictive value of a clinical phenotype after genetic testing uncertain and
environmentally dependent; the importance of a genetic variation may require a
professional consultation, but the designation of illness must necessarily arise from
an interactionbetweentheclient, the expert, and the environment inwhichtheclient
lives.
In summary, to modify an idea drawn from the currently popular pundit, Vaclav
Havel, it is hubris for medical geneticists to think that we will someday understand
everything. We can continue the struggle for reason, confident in failure and
affirming what we know to be right-that genetic information is personal, non-
discriminating, andnon-determining, and should remainthe individual's confidential
personal property.
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